Abstract 5857: Oligofructose Supplementation Decreases Blood Pressure and Improves Lipid Metabolism in Hypertensive People: A Randomized Controlled Trial
Background: Oligofructose (OFS), as a kind of prebiotics, apparent potential benefits for obesity and cardiovascular diseases. However, the effect of OFS on blood pressure is unknown.
Methods: A total of 96 adults (aged 47±12 yrs) with mild or borderline primary hypertension were enrolled in a prospective, randomized, double-blinded, placebo-controlled trial. A manual based self-management programme was performed in all participants for the homogenization in lifestyle. Compliance was monitored using serial contemporaneous food and lifestyle trackers. None of subjects received anti-hypertension drug therapy during the study period. Forty-eight subjects were randomly assigned to receive 20 g OFS per day (OFS group) or placebo (control group) for 12 weeks. Five subjects did not complete the trial. Primary study outcomes were changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Secondary outcomes included plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and body weight.
Results: The measured outcomes showed more beneficial changes in OFS group. At the end of treatment, the decrease of SBP was 6.9±2.5 mmHg in OFS group and 3.5±1.2 mmHg in control group (p < 0.001). The decrease of DBP was 7.3±2.6 mmHg in OFS group vs. 2.3±1.4 mmHg in control group (p < 0.001). Although there was no difference in HDL-C between the two groups (p < 0.05), participants in OFS group had significantly lowered plasma TC, LDL-C and TG than those in control group (p < 0.05). However, there was no significant difference in weight loss between the groups (p >0.05).
Conclusion: Oligofructose supplementation leads to a significant reduction in blood pressure and improvement in lipid metabolism in subjects with mild or borderline primary hypertension.